Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

24.66 -0.47 (-1.87%)
Streaming Delayed Price Updated: 10:27 AM EDT, Aug 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Acadia (ACAD) Q2 Revenue Rises 9%
Via The Motley Fool
Topics Intellectual Property
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Q2 2025 Earnings: Revenue Growth Meets Expectations, EPS Beats Estimates
Acadia Pharmaceuticals reports Q2 2025 earnings with $264.6M revenue (+9% YoY), EPS beats at $0.16. NUPLAZID & DAYBUE sales grow, reaffirms full-year guidance. Stock up 12.5% in past month. 
Via Chartmill
Earnings Scheduled For August 6, 2025
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) – A High-Growth Biotech Stock with Fair Valuation
ACADIA Pharmaceuticals (ACAD) offers strong growth, solid profitability, and fair valuation, making it a top pick for investors seeking affordable growth in biotech. 
Via Chartmill
The Analyst Verdict: ACADIA Pharmaceuticals In The Eyes Of 11 Experts
 
Via Benzinga
Earnings Scheduled For May 7, 2025
 
Via Benzinga
Demystifying ACADIA Pharmaceuticals: Insights From 5 Analyst Reviews
 
Via Benzinga
Earnings Scheduled For February 26, 2025
 
Via Benzinga
What Analysts Are Saying About ACADIA Pharmaceuticals Stock
 
Via Benzinga
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) – A Strong Growth Stock with Technical Breakout Potential
ACADIA PHARMACEUTICALS (NASDAQ:ACAD) shows strong growth fundamentals and a bullish technical setup, making it a noteworthy stock for growth investors. 
Via Chartmill
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity
Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal. 
Via Investor's Business Daily
Topics Intellectual Property
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - A Promising Growth Stock at a Reasonable Valuation
ACADIA PHARMACEUTICALS (NASDAQ:ACAD) offers strong growth potential with reasonable valuation, solid financial health, and improving profitability, making it a compelling candidate for growth... 
Via Chartmill
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) – A Strong Growth Stock with Technical Breakout Potential
ACADIA PHARMACEUTICALS (NASDAQ:ACAD) shows strong growth fundamentals and a bullish technical setup, making it a stock to watch for potential breakout opportunities. 
Via Chartmill
13 Analysts Assess ACADIA Pharmaceuticals: What You Need To Know
 
Via Benzinga
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - A Promising Affordable Growth Stock
ACADIA PHARMACEUTICALS (NASDAQ:ACAD) offers strong growth potential with reasonable valuation, solid financial health, and improving profitability, making it an interesting candidate for growth... 
Via Chartmill
JPMorgan Lifts Acadia Price Target After Nuplazid Patent Victory
Acadia wins Nuplazid patent case, extending protection to 2038, as JP Morgan boosts price target ahead of key appeal on the ‘740 COM patent. 
Via Benzinga
Topics Intellectual Property
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - A Promising Growth Stock at a Reasonable Valuation
ACADIA PHARMACEUTICALS (NASDAQ:ACAD) offers strong growth potential with reasonable valuation, solid financial health, and improving profitability, making it an interesting stock for growth investors. 
Via Chartmill
These Analysts Boost Their Forecasts On Acadia Pharmaceuticals
 
Via Benzinga
Forecasting The Future: 8 Analyst Projections For ACADIA Pharmaceuticals
 
Via Benzinga
Netflix To $1,220? Here Are 10 Top Analyst Forecasts For Monday
 
Via Benzinga
Acadia Pharmaceuticals (ACAD) Stock Explodes 26% After Patent Court Victory
ACADIA Pharmaceuticals stock jumped 26.4% Friday afternoon. Shares gained following a favorable court ruling. 
Via Benzinga
Topics Intellectual Property
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Top stock movements in today's session.
Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
Evolv Technologies, Quantum Computing, ACADIA Pharmaceuticals And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
The market is filled with gapping stocks in Friday's session.
Let's delve into the US markets on Friday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
NASDAQ:ACAD, an undervalued stock with good fundamentals.
ACADIA PHARMACEUTICALS INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:ACAD showcases decent financial health and profitability, coupled with an attractive price. 
Via Chartmill
While growth is established for NASDAQ:ACAD, the stock's valuation remains reasonable.
ACADIA PHARMACEUTICALS INC was identified as an affordable growth stock. NASDAQ:ACAD is showing great growth, but also scores well on profitability. At the same time it seems to be priced reasonably. 
Via Chartmill
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide
 
Via Benzinga
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.